CN107898815A - A kind of animal inactivation lactobacillus preparation and application thereof - Google Patents
A kind of animal inactivation lactobacillus preparation and application thereof Download PDFInfo
- Publication number
- CN107898815A CN107898815A CN201711284141.0A CN201711284141A CN107898815A CN 107898815 A CN107898815 A CN 107898815A CN 201711284141 A CN201711284141 A CN 201711284141A CN 107898815 A CN107898815 A CN 107898815A
- Authority
- CN
- China
- Prior art keywords
- inactivation
- lactobacillus
- animal
- preparation
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Include inactivation lactobacillus cell with lactobacillus preparation and application thereof, the preparation is inactivated the invention discloses a kind of animal, the inactivation lactobacillus cell includes the one or more in the bacterial strain of lactobacillus, Bifidobacterium or the Coccus inactivated；The animal further includes the one or more in prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils and active probiotic with inactivation lactobacillus preparation.The inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation and/or a kind of bacterial strain of the Bifidobacterium of inactivation.The inactivation lactobacillus cell is at least 108‑1011A/gram.Present invention additionally comprises be used to prevent in animal intestinal tract, dam reproductive organs (vagina and uterus), urethra, oral cavity or respiratory infection diseases medicine or sanitary health drug by above-mentioned animal inactivation lactobacillus preparation.Product of the present invention has the advantages that safe and reliable, applied widely.
Description
Technical field
The present invention relates to animal probiotics field, and in particular to and it is single made of a kind of inactivation lactic acid bacteria, or
To inactivate based on lactic acid bacteria, and composition (prebiotics, antibiotic, anodyne, medium chain fatty acid and its glycerine containing other compositions
Ester, plants essential oil, insect oils and active probiotic) preparation, it is raw for preventing animal rectum, dam (pig, cattle and sheep etc.)
Grow inflammation, pathogenic microorganism infection and the health care of organ (vagina and uterus), urethra etc..
Background technology
With the development of modern intensive aquaculture, every dam year litter size is continuously improved, while artificial insemination substitutes
Traditional mating fertilization, lack of standardization and sterilization of instruments is tight, Process of Insemination is vulnerable to microorganism infection due to operating, childbirth with
May also cause microorganism infection during midwifery, so as to cause birth canal, vulneratio uteri and infection, be susceptible to suffer from various diseases, as dam is anxious,
Chronic endometritis, retained afterbirth, vaginitis, trichomonad or candidal vaginitis, and difficult labour etc., seriously affect production effect
Rate.The above illness medicine based on chemical agent and antibiotic is currently mainly used made of suppository prevented.But these
The use of suppository can cause the microorganism species such as vagina, rectum to change, and severe patient can cause microecological balance to destroy, and beneficial bacterium is such as
Lactic acid bacteria is reduced；Meanwhile chemical agent and antibiotic etc. can cause the problems such as drug Resistance of Pathogenic Microorganism from Surface, occur weak curative effect, easily
Recurrence etc., shortcoming is obvious.It is perfect not enough and though the product such as active probiotic suppository has certain therapeutic effect, because of viable bacteria
Product is sensitive to environmental change, and transport needs whole cold chain with storage, therefore there are many use limitations.
Livestock and poultry diarrhea is also common intestines problem, and significant negative impact is caused to growth performance.Conventional control abdomen at present
The method rushed down is by adding various additives, such as antibiotic, zinc oxide, acidulant, probiotics in feed, by oral
The feed of the component containing the above and achieve the purpose that prevent diarrhea.Clinically then general the methods of using injection of antibiotics, treats abdomen
Rush down.But oral slowly effect, cultivation site injection operation can cause the stress reaction of animal.
Cultivated animals respiratory tract infection is also common disease, be easy to cause cross-infection, mixed infection and scabies secondary infection,
High risks are brought to aquaculture and cause huge economic losses.
The content of the invention
To solve the above problems, the present invention provides a kind of animal inactivation lactic acid bacteria system safe and reliable, prevention effect is good
Agent and application thereof, compared with antibiotics or live probiotic mushroom preparation, inactivation lactobacillus preparation of the invention is more stable, more may be used
Lean on, is safer, using more convenient, many restrictions of no viable bacteria class preparation.
The technical solution adopted by the present invention is：A kind of animal inactivation lactobacillus preparation, including inactivation lactobacillus cell, institute
State the one or more in the bacterial strain of lactobacillus of the inactivation lactobacillus cell including inactivation, Bifidobacterium or Coccus；Institute
State animal and further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plant essence with inactivation lactobacillus preparation
One or more in oil, insect oils and active probiotic.
A kind of purposes the present invention also provides animal with inactivation lactobacillus preparation, including above-mentioned animal is used into inactivation lactic acid bacteria
Preparation is used to prevent animal intestinal tract, dam (pig, ox, sheep etc.) reproductive organs (vagina and uterus), urethra, oral cavity and respiratory tract sense
Contaminate disease medicament or sanitary health drug.
The beneficial effects of the present invention are：Product of the present invention, which uses, glues animal intestinal tract, genital tract or oral cavity and respiratory tract
Film have compared with strongly adherent can inactivation lactic acid bacteria be active ingredient, available for animals' reproduction road or rectum health care, prevent it is viral,
Bacillary, fungoid genital tract, enteric infection, a variety of genital tracts and intestines problem, such as animal intestinal tract inflammation and diarrhea；Such as mother
Raise (pig, ox, sheep etc.) acute and chronic endometritis, retained afterbirth, vaginitis, trichomonad or candidal vaginitis, and difficult labour
Deng；Moreover it is possible to prevent animal urethra, oral cavity and respiratory tract infection.Compared with traditional prebiotic mushroom suppository, spray, inactivation
The unconditional pathogenicity of lactobacillus preparation, it is safer；Transport storage is more stable, more convenient without cold chain；Killed from antibiotic etc.
Bacterium, bacteriostatic agent influence, thus without withdrawal time, and use scope is wider.The preparation of the present invention program using inactivation lactic acid bacteria,
Not regrowth and breeding, thus can be used at the same time with antibiotic etc., play a role so as to cooperate with, while can effectively remain locally micro-
The ecological balance, reduction use negative effect caused by antibiotic, prevent that the microorganism species such as enteron aisle, vagina are disorderly, beneficial bacterium is such as
Lactic acid bacteria is reduced, or the generation of antibiotic-associated diarrhea.
Embodiment
For the technology contents that the present invention will be described in detail, the objects and the effects, it is explained below in conjunction with embodiment.
The design of most critical of the present invention is：Using lactobacillus cell and the prebiotics of inactivation, antibiotic, anodyne, in
One or more of collaborations in chain fatty acid and its glyceride, plants essential oil, insect oils or active probiotic are used for animal body
In enteron aisle, reproductive organs (vagina and uterus), urethra, oral cavity and respiratory infection diseases medicine, therapeutic effect is more preferable, security
Higher.
A kind of animal inactivation lactobacillus preparation, including inactivation lactobacillus cell, the inactivation lactobacillus cell include going out
One or more in the bacterial strain of lactobacillus living, Bifidobacterium or Coccus；Animal inactivation lactobacillus preparation
Further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils or active probiotic
In one or more.
As can be seen from the above description, the beneficial effects of the present invention are：Product of the present invention is used to animal intestinal tract and genitals
Official (vagina and uterus), and oral cavity and respiratory mucosa have compared with strongly adherent can lactic acid bacteria killed cells for effectively into
Point, available for animals' reproduction organ (vagina and uterus), rectum health care, diminish inflammation, prevent viral, bacillary or fungoid
The disease such as infection, a variety of genitals and intestinal inflammatory and cervical erosion, such as intestinal inflammatory and diarrhea；Such as dam (pig, ox, sheep)
Acute and chronic endometritis, retained afterbirth, vaginitis, trichomonad or bead-containing bacteria vaginitis, and difficult labour etc.；Moreover it is possible to prevent
Urethra, oral cavity and respiratory tract infection.
Preferably, the inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation or a kind of bifid of inactivation
The bacterial strain of Bacillus.
It is highly preferred that the inactivation lactobacillus cell includes at least a kind of lactobacillus of inactivation and a kind of bifid of inactivation
The composition of the bacterial strain of Bacillus.
Further, the inactivation lactobacillus cell is at least 108-1011A/gram, preferably at least contain 1010-1011
A/gram.
Preferably, the inactivation lactobacillus cell is one kind in the bacterial strain of lactobacillus, Bifidobacterium or Coccus
Or after a variety of fermentations respectively, cell, sterile water or sterile saline cleaning cell mud are centrifuged or be separated by filtration, is carried out after suspension
High-temperature inactivation；Preferably 60 DEG C -121 DEG C of inactivation temperature maintains -60 minutes 30 minutes；Ensure without lactobacillus cell living, at the same time
The form of cell is still complete, and percentage of head rice reaches 80%-90% or more；It is made after the bacteria suspension of acquisition high cell concentration or drying
Powder.
Further, the inactivation lactobacillus strains include but not limited to：Lactobacillus Jensenii (Lactobacillus
Jensenii) vagina separation strains 1153, Yue Shi lactobacillus (Lactobacillus johnsonii), Lactobacillus crispatus
(Lactobacillus crispatus), lactobacillus reuteri (Lactobacillus reuterii), Lactobacillus casei
(Lactobacillus casei), Lactobacillus salivarius (Lactobacillus salivarius), Lactobacillus animalis
(Lactobacillus animalis), Lactobacillus brevis (Lactobacillus breve), lactobacillus ruminis
(Lactobacillus ruminis), lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus gasseri
(Lactobacillus gasseri), Lactobacillus rhamnosus (Lactobacillus rhamnosus), lactobacillus plantarum
(Lactobacillus plantarum), lactobacillus fermenti (Lactobacillus fermentum), Lactobacillus delbrueckii strain breast
One or more in subspecies (Lactobacillus delbrueckii subsp.Lactis.).
Further, the Heat-killed Bifidobacterium On Microflora category bacterial strain (Bifidobacterium spp.) includes but not limited to：It is short
Bifidobacterium (Lactobacillus breve), two Bifidobacteriums (Bifidobacterium bifidum), chain bifid bar
Bacterium (Bifidobacterium catenulatum), bifidobacterium longum (Bifidobacterium longum), plant bifid bar
Bacterium (Bifidobacterium plantarum), bifidobacterium infantis (Bifidobacterium infantis), youth bifid
Bacillus (Bifidobacterium adolescentis), bifidobacterium lactis (Bifidobacterium lactis), tooth bifid
One or more in bacillus (Bifidobacterium dentium).
Further, the inactivation Coccus bacterial strain includes but not limited to：Enterococcus faecalis (Enterococcus
Faecalis), streptococcus fecalis (Streptococcus faecalis), enterococcus faecium (Enterococcus faecium), breast
Sour piece coccus (Pedioccoccusacidi lactici), thermophilus bacterial strain (Streptococcus thermophilus),
Pediococcus pentosaceus (Pediococcus pentosaceus), streptococcus lactis (Streptococcus lactis), Lactococcus lactis
One or more in (Lactococcus lactis).
Preferentially, the active probiotic also includes in the probiotics such as above-mentioned lactobacillus class, Bifidobacterium class and coccus
One or more.
Further, the active probiotic includes but not limited to：Bacillus subtilis, bacillus licheniformis, fragile plan
One or more in bacillus or clostridium butyricum.
Further, the prebiotics includes but not limited to：It is inulin, manna oligosacchride, oligofructose, galactooligosaccharide, low
One or more in xylan, fructooligosaccharide, oligoisomaltose.
Further, the plants essential oil includes but not limited to：Cinnamic acid, Thymol, eugenol, carvacrol, lemon
One or more in aldehyde, galic essential oil, litsea cubeba oil, oil of Cymbopogon winterianus and eucalyptus oil etc..
Further, the animal further includes other antifungal agents with inactivation lactobacillus preparation and other are pharmaceutically acceptable
Composition of medicine.
The antifungal agent includes but not limited to one kind or several in clotrimazole, Naftifine, nystatin, natamycin
Kind.
Further, the animal further includes antibacterial agent and other pharmaceutically acceptable group with inactivation lactobacillus preparation
Composite medicine.
The antibacterial agent includes but not limited to Ceftiofur, lincomycin, aureomycin, streptomysin and metronidazole etc..
Further, the anodyne is preferably ether etc..
Preferably, the medium chain fatty acid and its glyceride, are the laurate and Glycerol Monolaurate of 12 carbon.
Further, the medium chain fatty acid and its glyceride are included from -12 carbon fatty acid of 6 carbon and its single or multiple sweet ester,
The medium chain fatty acid includes the one or more in sour (C6), sad (C8), capric acid (C10) or laurate (C12).
Further, the animal can also include excipient with inactivation lactobacillus preparation, and the excipient includes long-chain
The glyceryl stearate of fatty glyceride, such as 18 carbon.
Further, the animal with inactivation lactobacillus preparation be suppository, tablet, capsule, soft capsule, pre-filling injection agent,
Ointment, lavage solution or mouth and nose spray.
As can be seen from the above description, the beneficial effects of the present invention are：Product of the present invention is to inactivate lactic acid bacteria as main component
The forms such as pre-filling injection agent, rectal suppository, capsule and mouth and nose spray are prepared as, with antibiotics or live probiotic mushroom preparation
To compare, invention formulation effect is more stable, more reliable, safer, using more convenient, without many restrictions of viable bacteria class preparation,
The microecological balance in animal body can be maintained at the same time.
Preferably, the animal is suppository or mouth and nose spray with inactivation lactobacillus preparation.
As can be seen from the above description, the beneficial effects of the present invention are：By mouth and nose spray offer medicine treatment respiratory tract infection or
Rectal suppository dispensing prevention diarrhea, medicine is directly launched at sufferer, take effect speed faster.
A kind of purposes the present invention also provides animal with inactivation lactobacillus preparation, including above-mentioned animal is used into inactivation lactic acid bacteria
Formulation application is in prevention animal intestinal tract, dam (pig, ox, sheep etc.) reproductive organs (vagina, uterus), urethra, oral cavity or respiratory tract
In infectious disease medicine or the medicine of health care.
Further, it is various dynamic with inactivation lactobacillus preparation to be applicable to aquatic products, herding, poultry etc. to animal of the invention
Thing.
" include but not limited to " to each mean alleged by the present invention in addition to one or more of in the object including enumerating, can be with
Including othering the material with similarity, and following newfound analog.
Embodiment 1：Animal of the present invention is as follows with the preparation method that lactic acid bacteria powder is inactivated in inactivation lactobacillus preparation：It can join
The patent ZL200810068138.X for examining this research department is implemented, specific as follows：Lactobacillus, the bifid in above-mentioned lactic acid bacteria are taken respectively
Bacillus or coccus pure culture, activation and picking single bacterium colony in solid-state MRS cultures；Picking single bacterium colony accesses MRS or changes
Good liquid MRS culture mediums, when 30 DEG C of -37 DEG C of culture 12-18 are small, cell at this time is in exponential phase, and cell number reaches
108-109CFU/ml.Above-mentioned ready seed is accessed in liquid fermentation base in 3%-5% (v/v) ratio, it is static or slow
Stirring, when 30 DEG C of -37 DEG C of culture 18-24 are small, cell number is up to 10 at this time8-109CFU/ml；Stop fermentation, side is stirred and risen
Height fermentation base temperature maintains 30 minutes, to ensure cell inactivation, but lactobacillus cell is still complete, and percentage of head rice reaches to 80 DEG C
90%；Centrifugation, collects the lactobacillus cell of inactivation；Sterile water or sterile saline cleaning are added, removes remaining fermentation base
With solable matter；Take appropriate excipient, such as glucose, oligofructose, or starch etc., in proportion with the killed cells of collection
Wet bacterium mud mixing；Vacuum drying or vacuum freeze drying；Low-temperature grinding, the sieving of 80-100 mesh；Obtain going out for single lactic acid bacteria
Living cells high concentrate clust, cell content are 1 × 1010-2×1010A/gram.Load sterile vacuum bag, sealing preservation, is sticked
Label, it is spare.
Embodiment 2：A kind of preparation of the animal inactivation compound suppository of lactic acid bacteria：Inactivation lactic acid bacteria prepared by Example 1
15 parts of powder, wherein take 7.5 parts of the lactobacillus acidophilus of inactivation respectively, 7.5 parts of bifidobacterium infantis, both killed cells numbers are
2×1010A/gram；5 parts of oligofructose, 80 parts of tristerin；Lactic acid bacteria will be inactivated, oligofructose adds the tristearin of fusing
In acid glyceride, vaginal plug mould is fed into after stirring evenly, cools down, scabble, Qi Mo, packing animal up to suppository form with going out
Live acid bacteria preparation.Every or about 1 gram -10 grams of per unit suppository, according to using depending on animal body size.
Embodiment 3 inactivates the purposes of lactobacillus preparation for a kind of animal：By the animal of the embodiment 2 sour bacteria preparation of inactivation
For preventing the infection of sow birth canal, prevent hysteritis or endometritis.
Select natural labor, grown in vain without breeding difficulty through producing standby pregnant sow 60, every group 30, be divided into experimental group and control group.
Experimental group is in breeding the last week, and with special pusher by the suppository in 1 embodiment 1,5g containing effective ingredient, is pushed into uterus or the moon
Road；Control group does not process, other rearing conditions and management operation are consistent.
Testing result finds that between test group sow vaginal mucus pH maintains 6.0-6.8, and control group pH is 7.2-
Between 8.0, significant difference (P<0.05)；Test group Lactobacillus vaginalis number about 1 × 107-108CFU/ml, control group about 1 ×
106-107CFU/ml, the Lactobacillus vaginalis number of test group substantially increase (P<0.05).And by long-term it has been observed that repeatedly
The experimental group sow postpartum reproductive tract infection of inactivation lactic acid bacteria of the invention and the number of inflammation has been used to reduce 90% than control group,
Significant difference (P<0.05).And Recovery situation, the health status of piglet of experimental group are better than control group.Therefore, originally
Invention product has good preventive effect.
Embodiment 4 inactivates lactic acid bacteria complex capsule preparation for a kind of animal：Inactivation lactic acid bacteria powder prepared by Example 1
50 parts (wherein 20 parts of Lactobacillus salivarius, 20 parts of bifidobacterium adolescentis, 10 parts of lactic acid chain bacterium balls), the killed cells number of three's original powder
It is 2 × 1010A/gram；5 parts of iodoform, 5 parts of the active polypeptide lactobacillus powder of coating, 5 parts of Glycerol Monolaurate, magnesium stearate 5
Part, 30 parts of lactose；Mentioned component is quantified into mixing, after stirring evenly, it is 1 × 10 to inactivate lactobacillus cell in pulvis at this time10A/
G, pours into capsule.
Embodiment 5：The animal of the embodiment 4 sour bacterium capsule preparations of inactivation are applied to treatment sow reproductive tract infection.Choosing
The sow 50 with reproductive tract infection is selected, is divided into experimental group and control group, every group 25.Experimental group is used in embodiment 4
Capsule, twice daily, one piece every time, 5 days as one therapeutic course, the therapeutic effect after a course for the treatment of is as shown in table 1 below, and table 1 is the present invention
The treatment results statistical form of embodiment 5.
The treatment results statistical form of 1 embodiment of the present invention 5 of table
| Group | Head number | Cure head number | Improve head number | Invalid head number | It is efficient |
| Experimental group | 25 | 18 | 5 | 2 | 92% |
| Control group | 25 | 0 | 2 | 23 | 8.0% |
As it can be seen from table 1 being treated using medicine of the present invention, therapeutic effect is up to 92%, it can be achieved that good controls
Therapeutic effect, observe experimental group can effectively treat the reproductive tract infection of sow.
Embodiment 6：A kind of animal inactivation lactobacillus preparation：15 parts of inactivation lactic acid bacteria prepared by Example 1, wherein dividing
7.5 parts of the lactobacillus acidophilus of inactivation is not taken, and 7.5 parts of bifidobacterium infantis, both killed cells numbers are 2 × 1010A/gram；
1 part of lincomycin, 1 part of clotrimazole, 3 parts of oligofructose, 80 parts of tristerin；Will inactivation lactic acid bacteria, lincomycin, gram mould
Azoles, oligofructose are added in the tristerin of fusing, are fed into after stirring evenly in vaginal plug mould, are cooled down, scabble, open
Mould, the animal inactivation lactobacillus preparation for packing suppository form to obtain the final product.Every or about 1 gram -10 grams of per unit suppository, according to use
Depending on animal body size.
Embodiment 7：A kind of animal is with the inactivation compound suppository formulations of lactic acid bacteria in milk cow metria prophylactic applications：Selection
Firm natural labor through milking cow 60, be divided into experimental group and control group, every group 30, experimental group will be real after afterbirth comes off in postpartum
The suppository described in example 6 is applied, 5g containing active ingredient is pushed into cow uteri, daily one, is used within continuous three days, control group does not make
With remaining Routine Management is identical.Observe experimental group postpartum uterine infection declines to a great extent than control group, decline up to 83.3%, it is poor
Different significantly (P<0.05), and postpartum experimental group recovery situation is better than control group.Therefore, the present invention is to the pre- of milk cow metria
It is anti-to work well.
Embodiment 8：A kind of animal, which is used, inactivates lactobacillus preparation, 30 parts of inactivation lactic acid bacteria powder in Example 1, wherein knurl
15 parts of stomach lactobacillus, 15 parts of enterococcus faecium, both killed cells numbers are 2 × 1010A/gram；45 parts of plants essential oil, wherein meat
20 parts of cinnamic aldehyde, 20 parts of Thymol, 5 parts of galic essential oil, 10 parts of oligofructose, 2 parts of iodoform, 3 parts of ether, 10 parts of magnesium stearate,
Pour into capsule, every capsule is 5 grams.
Embodiment 9：A kind of application of animal with inactivation lactobacillus preparation in milk cow lochia discharges serious nursing：Choosing
Select lochia and discharge serious milk cow 50, be divided into experimental group and control group, experimental group takes the glue of gained in two embodiments 8
Capsule, which is cut off, to be dissolved in the warm water of 200ml 35-40 DEG C, and preparation is sent into uterus with ox with vas deferens, once a day, continues three days,
Control group does not process, other management operations are consistent.Observe, experimental group lochia discharge situation is obviously improved after three days, is compared
Improve according to a group lochia discharge situation up to more than 90%, positive effect, and it is excellent to test the overall recovery situation of milk cow, feed intake etc.
In control group.
Embodiment 10：A kind of animal inactivation lactobacillus preparation：15 parts of inactivation lactic acid bacteria part in Example 1, wherein
7.5 parts of lactobacillus acidophilus, 7.5 parts of Lactobacillus rhamnosus, killed cells number is 2 × 1010A/gram, black soldier flies insect oils 25
Part, 3 parts of Lactococcus lactis living, 57 parts of tristerin.Will inactivation lactic acid bacteria and Lactococcus lactis and black soldier flies insect oils
After mixing, add in the tristerin of dissolving, be fed into after stirring evenly in vaginal plug mould, cool down, scabble, Qi Mo, bag
The animal inactivation lactobacillus preparation up to suppository form is filled, active ingredient is 2g every.
Embodiment 11：A kind of application of animal with inactivation lactobacillus preparation in diarrhea piggy prevents：Selective body heavy phase is near,
90 of about 25kg suffer from the piggy of mild diarrhea, and after diagnosing, which meets bacillary and virus diarrhea symptom.Will
Piggy is divided into preparation group, antibiotic group, control group, every group 30.Gained in the daily rectally embodiment 10 of preparation group
Suppository 2, once a day, 5 days as one therapeutic course；Antibiotic group is handled according to conventional antibiotic treatment, and control group does not process, its
It is consistent that he manages operation.It is as shown in table 2 to take the record of the inspection result after a course for the treatment of, table 2 is the treatment of the embodiment of the present invention 11
As a result statistical form.
The treatment results statistical form of 2 embodiment of the present invention 11 of table
| Group | Originate head number | Cure head number | Improve head number | Invalid head number | Efficient (%) |
| Antibiotic group | 30 | 19 | 8 | 3 | 90 |
| Preparation group | 30 | 17 | 9 | 4 | 86 |
| Control group | 30 | 5 | 8 | 17 | 43 |
From Table 2, it can be seen that the bacterium and virus diarrhea of inactivation lactic acid bacteria and insect oils compound formulation to piggy
There is good prevention effect.
Embodiment 12：A kind of animal, which is used, inactivates lactobacillus preparation, 45 parts of inactivation lactic acid bacteria in Example 1, wherein saliva
15 parts of liquid lactobacillus, 15 parts of lactobacillus plantarum, 15 parts of bifidobacterium longum, 10 parts of oligofructose, aureomycin 5 parts (25mg/kg) are sliding
40 parts of mountain flour, uniformly spray is made in rear 80-100 mesh sieving to mixed grinding.
Embodiment 13：A kind of application of animal with inactivation lactobacillus preparation in respiratory tract infection piggy is treated：Selective body
Again etc. similar in each side condition, the piggy 60 of respiratory tract infection of pigs symptom is had, is divided into experimental group and control group, every group
30, obtained spray in experimental group daily administration embodiment 12, twice daily, 7 days as one therapeutic course, control group does not process,
Other management operations are consistent.It turns out that experimental group respiratory tract infection symptom is almost recovered, up to 86%, control group then improves not
Greatly, the obvious (p of difference<0.05).The above results illustrate that respiratory tract infection of the said preparation to pig also has good effect.
" part " in the present invention each means parts by weight.
In conclusion the present invention provides a kind of animal inactivation lactobacillus preparation and application thereof, using the present invention program system
Standby animal can be widely used for multi-infection disease with inactivation lactobacillus preparation, and the therapeutic effect of product of the present invention is good, controls
More rate is high.
The foregoing is merely the embodiment of the present invention, is not intended to limit the scope of the invention, every to utilize this hair
The equivalents that bright description is made, are directly or indirectly used in relevant technical field, are similarly included in this hair
In bright scope of patent protection.
Claims (10)
- A kind of 1. animal inactivation lactobacillus preparation, it is characterised in that：Including inactivating lactobacillus cell, the inactivation lactic acid bacteria is thin Born of the same parents include the one or more in the bacterial strain of lactobacillus, Bifidobacterium or the Coccus inactivated；Animal inactivation breast Sour bacteria preparation further include prebiotics, antibiotic, anodyne, medium chain fatty acid and its glyceride, plants essential oil, insect oils and One or more in active probiotic.
- 2. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The inactivation lactobacillus cell is extremely A kind of lactobacillus including inactivation and/or a kind of bacterial strain of the Bifidobacterium of inactivation less.
- 3. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：It is described inactivation lactobacillus cell be After one or more fermentations in the bacterial strain of lactobacillus, Bifidobacterium or Coccus, made of after being inactivated and being dried Powder.
- 4. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The active probiotic include but The one kind or several being not limited in biodiasmin, bacillus subtilis, bacillus licheniformis, bacteroides fragilis or clostridium butyricum Kind.
- 5. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The prebiotics includes but unlimited One kind or more in inulin, manna oligosacchride, oligofructose, galactooligosaccharide, xylo-oligosaccharide, fructooligosaccharide, oligoisomaltose Kind.
- 6. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The animal uses inactivation lactic acid bacteria Preparation further includes antifungal agent or antibacterial agent and other pharmaceutically acceptable combinations.
- 7. according to the animal inactivation lactobacillus preparation described in claim 1, it is characterised in that：The medium chain fatty acid and its Glyceride includes but not limited to the one or more in caproic acid, octanoic acid, capric acid, laurate.
- 8. according to the animal inactivation lactobacillus preparation described in claim 1, it is characterised in that：The plants essential oil include but It is not limited to cinnamic acid, Thymol, eugenol, carvacrol, citral, galic essential oil, litsea cubeba oil, eucalyptus oil, lemongrass essence One or more in oil；The insect oils include but not limited to the one or more in Heisui River gadfly oil, yellow meal worm worm oil.
- 9. animal according to claim 1 inactivation lactobacillus preparation, it is characterised in that：The animal uses inactivation lactic acid bacteria Preparation is suppository, tablet, mouth and nose spray, capsule, soft capsule, pre-filling injection agent, ointment or lavage solution.
- It is 10. a kind of such as claim 1-9 any one of them animal purposes of inactivation lactobacillus preparation, it is characterised in that：Bag Include and be used to prevent animal intestinal tract, dam reproductive organs, urethra, oral cavity, respiratory tract sense by above-mentioned animal inactivation lactobacillus preparation Contaminate in disease medicament or sanitary health drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711284141.0A CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711284141.0A CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898815A true CN107898815A (en) | 2018-04-13 |
Family
ID=61864915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711284141.0A Pending CN107898815A (en) | 2017-12-07 | 2017-12-07 | A kind of animal inactivation lactobacillus preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898815A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109837229A (en) * | 2019-04-11 | 2019-06-04 | 河北维尔利动物药业集团有限公司 | The preparation method of clostridium butyricum composite bacteria liquid for poultry |
| CN111184140A (en) * | 2020-01-17 | 2020-05-22 | 金华市农业科学研究院 | Feed additive for improving production performance of laying quails |
| CN112574919A (en) * | 2020-12-18 | 2021-03-30 | 广州市微生物研究所有限公司 | Mycosporin secretion type probiotic agent as well as preparation method and application thereof |
| CN113645959A (en) * | 2018-12-19 | 2021-11-12 | 健康牛公司 | Ready-to-use probiotic composition and uses thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1568365A (en) * | 2001-10-12 | 2005-01-19 | 雷丁大学 | Composition comprising a lactobacillus pentosus strain and uses thereof |
| CN101069700A (en) * | 2007-05-24 | 2007-11-14 | 郭兴华 | Composition for preventing manmmal vagina infection and use |
| CN101612169A (en) * | 2008-06-27 | 2009-12-30 | 生物源生物技术（深圳）有限公司 | Lactobacillus micro-ecological preparation of deactivation and preparation method thereof |
| CN101827600A (en) * | 2007-08-17 | 2010-09-08 | 雀巢产品技术援助有限公司 | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition used for inhibiting inflammatory response and resisting vaginitis |
| JP2016214107A (en) * | 2015-05-15 | 2016-12-22 | フロイント産業株式会社 | Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium |
| WO2017014929A1 (en) * | 2015-07-23 | 2017-01-26 | The Procter & Gamble Company | Patch containing microorganism |
| CN106720938A (en) * | 2016-11-10 | 2017-05-31 | 四川理工学院 | A kind of compound symphysis unit probiotics and preparation method thereof |
| CN107198675A (en) * | 2017-04-20 | 2017-09-26 | 广东丸美生物技术股份有限公司 | A kind of double-deck Essence with maintenance and senile-resistant efficacy and preparation method and application |
-
2017
- 2017-12-07 CN CN201711284141.0A patent/CN107898815A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
| CN1568365A (en) * | 2001-10-12 | 2005-01-19 | 雷丁大学 | Composition comprising a lactobacillus pentosus strain and uses thereof |
| CN101069700A (en) * | 2007-05-24 | 2007-11-14 | 郭兴华 | Composition for preventing manmmal vagina infection and use |
| CN101827600A (en) * | 2007-08-17 | 2010-09-08 | 雀巢产品技术援助有限公司 | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| CN101612169A (en) * | 2008-06-27 | 2009-12-30 | 生物源生物技术（深圳）有限公司 | Lactobacillus micro-ecological preparation of deactivation and preparation method thereof |
| CN102835657A (en) * | 2011-06-20 | 2012-12-26 | 丰华生物科技股份有限公司 | Lactic acid bacteria-containing food composition and pharmaceutical composition used for inhibiting inflammatory response and resisting vaginitis |
| JP2016214107A (en) * | 2015-05-15 | 2016-12-22 | フロイント産業株式会社 | Production method of powder composition containing dead cell of lactic acid bacterium and/or bifidobacterium |
| WO2017014929A1 (en) * | 2015-07-23 | 2017-01-26 | The Procter & Gamble Company | Patch containing microorganism |
| CN106720938A (en) * | 2016-11-10 | 2017-05-31 | 四川理工学院 | A kind of compound symphysis unit probiotics and preparation method thereof |
| CN107198675A (en) * | 2017-04-20 | 2017-09-26 | 广东丸美生物技术股份有限公司 | A kind of double-deck Essence with maintenance and senile-resistant efficacy and preparation method and application |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113645959A (en) * | 2018-12-19 | 2021-11-12 | 健康牛公司 | Ready-to-use probiotic composition and uses thereof |
| CN109837229A (en) * | 2019-04-11 | 2019-06-04 | 河北维尔利动物药业集团有限公司 | The preparation method of clostridium butyricum composite bacteria liquid for poultry |
| CN111184140A (en) * | 2020-01-17 | 2020-05-22 | 金华市农业科学研究院 | Feed additive for improving production performance of laying quails |
| CN112574919A (en) * | 2020-12-18 | 2021-03-30 | 广州市微生物研究所有限公司 | Mycosporin secretion type probiotic agent as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200069749A1 (en) | Lactobacillus-based ecoli inhibition | |
| RU2316586C2 (en) | PROBIOTIC STRAINS OF Lactobacillus (VARIANTS) AND THEIR USING | |
| FI122247B (en) | Probiotic preparation for the prevention or treatment of dogs gastrointestinal disorders | |
| CN107815432B (en) | Inactivated lactobacillus preparation for human and application thereof | |
| CN107898815A (en) | A kind of animal inactivation lactobacillus preparation and application thereof | |
| US8222020B2 (en) | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 | |
| CN1843385A (en) | Enteral microecological formulation and its preparation process | |
| CN102984954A (en) | Animal feed for calves for conditioning the intestinal flora | |
| CN103409334B (en) | Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen | |
| CN108753650A (en) | Enterococcus faecium and compound micro-ecological preparation prepared therefrom | |
| CN109402002A (en) | Lactobacillus gasseri and application thereof in preparation of premature delivery prevention medicine | |
| CN107714672B (en) | A kind of woman's vagina active probiotic gel packing and preparation method thereof | |
| WO2003039260A2 (en) | Probiotic compositions | |
| US20240066078A1 (en) | Strains, compositions and methods of use | |
| CN103333830B (en) | Pig source enterococcus faecalis, microbial ecological agent and application thereof | |
| Boaventura et al. | The benefits of probiotics in human and animal nutrition | |
| JP4243622B2 (en) | Livestock breeding method | |
| CN101450083B (en) | Use of clostridium butyricum in preparing composition for treating newborn feeding intolerance | |
| CN113186118B (en) | Composite probiotic preparation for improving sow productivity and preparation method thereof | |
| KR100993562B1 (en) | Lactobacillus strains | |
| CN116801893A (en) | Strains, compositions and methods of use | |
| CN108354952A (en) | Vagina infusion and its mixing arrangement set group and application method | |
| CN117821309B (en) | Lactobacillus rhamnosus Lr-HS56 and application thereof in female private products | |
| US20240050493A1 (en) | Strains, compositions and methods of use | |
| Eriksson | The effect of probiotic administration on piglets perfor-mance and intestinal microbiota |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180413 |